Clinical Trial Update: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating cadonilimab in combination with FOLFOXIRI and bevacizumab as first-line therapy for metastatic MSS colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cadonilimab
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN